{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:14:14Z","timestamp":1781550854925,"version":"3.54.5"},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"40","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed to systematically investigate whether anti-androgens could\nsignificantly reduce Obsessive-Compulsive Disorder (OCD) symptoms compared to placebo or usual\ncare in OCD patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>PubMed, EMBASE, CENTRAL and International Clinical Trials Registry Platform\n(ICTRP) databases were searched up to October 2018 using relevant keywords. All randomized and if\nnot available non-randomized studies conducted on a population including OCD patients who were\nadministered with anti-androgen, which reported changes in their symptoms, were included. The studies\non compulsive hypersexuality were excluded. Required data were extracted from full-text of the\nincluded articles by two independent authors. One randomized and four non-randomized trials were\nfound.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> The only randomized trial showed that flutamide, an anti-androgen agent, was effective in\nreducing compulsion scores in male OCD patients with comorbid Tourette syndrome, compared to\nplacebo. Three out of four non-randomized trials showed that different anti-androgens including\nfinasteride, cyproterone acetate and triptorelin were effective in reducing OCD symptoms. The only\nstudy, which failed to show the efficacy of an anti-androgen agent, administered OCD patients with\nflutamide. Despite the positive results, available studies provide the evidence with low quality based\non the Grades of Recommendation, Assessment, Development and Evaluation Working Group\n(GRADE) approach.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions :<\/jats:title>\n<jats:p>Available studies are not sufficient for a precise answer to our study question. There is\nstill a need for further large randomized blinded clinical trials to evaluate the effectiveness of antiandrogens\nin OCD patients. It is recommended that gender, comorbidities and subscales of Yale-\nBrown Obsessive-Compulsive Score (Y-BOCS) should be considered in designing the studies and\ninterpreting their results.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666191209142209","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T13:42:07Z","timestamp":1575898927000},"page":"6825-6836","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-Androgen Drugs in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-9864","authenticated-orcid":true,"given":"Homa","family":"Nomani","sequence":"first","affiliation":[{"name":"School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-8634","authenticated-orcid":true,"given":"Amir Hooshang","family":"Mohammadpour","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-5713","authenticated-orcid":true,"given":"Seyed Mohammad Hassan","family":"Moallem","sequence":"additional","affiliation":[{"name":"School of Medicine, Mashhad University of Medical Sciences, Mashhad,Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-2963","authenticated-orcid":true,"given":"Mahdi Jannati","family":"YazdanAbad","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-1971","authenticated-orcid":true,"given":"George E.","family":"Barreto","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Limerick, Limerick,Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-1444","authenticated-orcid":true,"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Halal Research Center of IRI, FDA, Tehran,Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.psc.2014.06.004","volume":"37","author":"Goodman W.K.","year":"2014","unstructured":"Goodman W.K.; Grice D.E.; Lapidus K.A.; Coffey B.J.; Obsessive-compulsive disorder. Psychiatr Clin North Am 2014,37(3),257-267","journal-title":"Psychiatr Clin North Am"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.brat.2014.02.001","volume":"56","author":"Lewin A.B.","year":"2014","unstructured":"Lewin A.B.; Park J.M.; Jones A.M.; Crawford E.A.; De Nadai A.S.; Menzel J.; Arnold E.B.; Murphy T.K.; Storch E.A.; Family-based exposure and response prevention therapy for preschool-aged children with obsessive-compulsive disorder: a pilot randomized controlled trial. Behav Res Ther 2014,56,30-38","journal-title":"Behav Res Ther"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"Ruscio A.M.","year":"2010","unstructured":"Ruscio A.M.; Stein D.J.; Chiu W.T.; Kessler R.C.; The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010,15(1),53-63","journal-title":"Mol Psychiatry"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","volume":"132","author":"Pittenger C.","year":"2011","unstructured":"Pittenger C.; Bloch M.H.; Williams K.; Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology and treatment. Pharmacol Ther 2011,132(3),314-332","journal-title":"Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctim.2016.03.018","volume":"27","author":"Jahanbakhsh S.P.","year":"2016","unstructured":"Jahanbakhsh S.P.; Manteghi A.A.; Emami S.A.; Mahyari S.; Gholampour B.; Mohammadpour A.H.; Sahebkar A.; Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: a randomized double-blind placebo-controlled trial. Complement Ther Med 2016,27,25-29","journal-title":"Complement Ther Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jad.2013.03.014","volume":"150","author":"Hofmeijer-Sevink M.K.","year":"2013","unstructured":"Hofmeijer-Sevink M.K.; van Oppen P.; van Megen H.J.; Batelaan N.M.; Cath D.C.; van der Wee N.J.A.; van den Hout M.A.; van Balkom A.J.; Clinical relevance of comorbidity in obsessive compulsive disorder: the Netherlands OCD Association study. J Affect Disord 2013,150(3),847-854","journal-title":"J Affect Disord"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0193-953X(18)30148-5","volume":"16","author":"McDougle C.J.","year":"1993","unstructured":"McDougle C.J.; Goodman W.K.; Leckman J.F.; Price L.H.; The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am 1993,16(4),749-766","journal-title":"Psychiatr Clin North Am"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/b978-0-444-53630-3.00008-7","volume":"186","author":"Reddy D.S.","year":"2010","unstructured":"Reddy D.S.;  Neurosteroids: endogenous role in the human brain and therapeutic potentials  Prog Brain Res 2010,186,113-137","journal-title":"Neurosteroids: endogenous role in the human brain and therapeutic potentials  Prog Brain Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.pnpbp.2009.06.013","volume":"33","author":"Umathe S.N.","year":"2009","unstructured":"Umathe S.N.; Vaghasiya J.M.; Jain N.S.; Dixit P.V.; Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009,33(7),1161-1166","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=10","first-page":"523","volume":"67","author":"Gaikwad U.","year":"2010","unstructured":"Gaikwad U.; Parle M.; Kumar A.; Gaikwad D.; Effect of ritanserin and leuprolide alone and combined on marble-burying behavior of mice. Acta Pol Pharm 2010,67(5),523-527","journal-title":"Acta Pol Pharm"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejphar.2007.02.016","volume":"563","author":"Uday G.","year":"2007","unstructured":"Uday G.; Pravinkumar B.; Manish W.; Sudhir U.; LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice. Eur J Pharmacol 2007,563(1-3),155-159","journal-title":"Eur J Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0090-4295(01)01247-X","volume":"58","author":"Lieberman R.","year":"2001","unstructured":"Lieberman R.; Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology 2001,58(2)(Suppl. 1),83-90","journal-title":"Urology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1046\/j.1464-410X.2003.04026.x","volume":"91","author":"Anderson J.","year":"2003","unstructured":"Anderson J.; The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003,91(5),455-461","journal-title":"BJU Int"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00004714-199808000-00013","volume":"18","author":"Peterson B.S.","year":"1998","unstructured":"Peterson B.S.; Zhang H.; Anderson G.M.; Leckman J.F.; A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette\u2019s syndrome. J Clin Psychopharmacol 1998,18(4),324-331","journal-title":"J Clin Psychopharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1016\/S0924-977X(09)70439-0","volume":"19","author":"Bini V.","year":"2009","unstructured":"Bini V.; Frau R.; Collu M.; Paba S.; Devoto P.; Marrosu F.; Bortolato M.; Blockade of 5-alpha reductase reduces compulsive behaviors in mice. Eur Neuropsychopharmacol 2009,19,S296-S297","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.30906\/0869-2092-2018-81-2-7-11]","volume":"81","author":"Kudryashov N.V.","year":"2018","unstructured":"Kudryashov N.V.; Kalinina T.S.; Kasabov K.A.; Shimshirt A.A.; Volkova A.V.; Zhmurenko L.A.; Voronina T.A.; The role of neurosteroids metabolism in anticompulsive effect of pyrazole[c]pyridine derivative gizh-72. Eksperimental\u2019naya i Klinicheskaya Farmakologiya 2018,81(12),7-11","journal-title":"Eksperimental\u2019naya i Klinicheskaya Farmakologiya"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/01.yic.0000224793.51900.cb]","volume":"22","author":"Eriksson T.","year":"2007","unstructured":"Eriksson T.; Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin. Int Clin Psychopharmacol 2007,22(1),57-61","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10517-016-3418-y","volume":"161","author":"Kudryashov N.V.","year":"2016","unstructured":"Kudryashov N.V.; Kalinina T.S.; Zhmurenko L.A.; Voronina T.A.; Anticompulsive activity of a new pyrazolo[C]pyridine derivative GIZh-72 under conditions of unpredictable chronic mild stress. Bull Exp Biol Med 2016,161(3),377-380","journal-title":"Bull Exp Biol Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1600-0447.1986.tb10591.x","volume":"73","author":"Casas M.","year":"1986","unstructured":"Casas M.; Alvarez E.; Duro P.; Garcia-Ribera C.; Udina C.; Velat A.; Abella D.; Rodriguez-Espinosa J.; Salva P.; Jan\u00e9 F.; Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand 1986,73(2),221-222","journal-title":"Acta Psychiatr Scand"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4088\/JCP.v60n0704","volume":"60","author":"Altemus M.","year":"1999","unstructured":"Altemus M.; Greenberg B.D.; Keuler D.; Jacobson K.R.; Murphy D.L.; Open trial of flutamide for treatment of obsessive-compulsive disorder. J Clin Psychiatry 1999,60(7),442-445","journal-title":"J Clin Psychiatry"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/mds.23810","volume":"26","author":"Muroni A.","year":"2011","unstructured":"Muroni A.; Paba S.; Puligheddu M.; Marrosu F.; Bortolato M.; A preliminary study of finasteride in Tourette syndrome. Mov Disord 2011,26(11),2146-2147","journal-title":"Mov Disord"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1600-0447.1988.tb06333.x","volume":"78","author":"Feldman J.D.","year":"1988","unstructured":"Feldman J.D.; Noshirvani H.; Chu C.; Improvement in female patients with severe obsessions and\/or compulsions treated with cyproterone acetate. Acta Psychiatr Scand 1988,78(2),254","journal-title":"Acta Psychiatr Scand"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1176\/appi.ajp.157.3.483","volume":"157","author":"Eriksson T.","year":"2000","unstructured":"Eriksson T.; Antiandrogenic treatment for obsessive-compulsive disorder. Am J Psychiatry 2000,157(3),483-483","journal-title":"Am J Psychiatry"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/0278-5846(96)00084-X","volume":"20","author":"Chouinard G.","year":"1996","unstructured":"Chouinard G.; B\u00e9langer M.C.; Beauclair L.; Sultan S.; Murphy B.E.P.; Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report. Prog Neuropsychopharmacol Biol Psychiatry 1996,20(6),1067-1079","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1176\/appi.ajp.2007.07060978","volume":"164","author":"Bortolato M.","year":"2007","unstructured":"Bortolato M.; Muroni A.; Marrosu F.; Treatment of Tourette\u2019s syndrome with finasteride. Am J Psychiatry 2007,164(12),1914-1915","journal-title":"Am J Psychiatry"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4306\/pi.2015.12.4.538","volume":"12","author":"Erbay L.G.","year":"2015","unstructured":"Erbay L.G.; Kartalci S.; Neurosteroid levels in patients with obsessive-compulsive disorder. Psychiatry Investig 2015,12(4),538-544","journal-title":"Psychiatry Investig"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jpsychires.2008.04.007","volume":"43","author":"Bigos K.L.","year":"2009","unstructured":"Bigos K.L.; Folan M.M.; Jones M.R.; Haas G.L.; Kroboth F.J.; Kroboth P.D.; Dysregulation of neurosteroids in obsessive compulsive disorder. J Psychiatr Res 2009,43(4),442-445","journal-title":"J Psychiatr Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00702-012-0805-z]","volume":"119","author":"Lange K.W.","year":"2012","unstructured":"Lange K.W.; Lange K.M.; Hauser J.; Tucha L.; Tucha O.; Circadian rhythms in obsessive-compulsive disorder. J Neural Transm (Vienna) 2012,119(10),1077-1083","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1016\/S0924-977X(09)70439-0","volume":"19","author":"Bini V.","year":"2009","unstructured":"Bini V.; Frau R.; Collu M.; Paba S.; Devoto P.; Marrosu F.; Bortolato M.P.; 1. d. 017 Blockade of 5-alpha reductase reduces compulsive behaviors in mice. Eur Neuropsychopharmacol 2009,19,S296-S297","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0010-7824(79)80048-7","volume":"20","author":"de la Torre B.","year":"1979","unstructured":"de la Torre B.; Nor\u00e9n S.; Hedman M.; Diczfalusy E.; Effect of cyproterone acetate (CPA) on gonadal and adrenal function in men. Contraception 1979,20(4),377-396","journal-title":"Contraception"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/pros.2990020309","volume":"2","author":"Geller J.","year":"1981","unstructured":"Geller J.; Albert J.; Nachtsheim D.A.; Loza D.; Geller S.; The effects of flutamide on total DHT and nuclear DHT levels in the human prostate. Prostate 1981,2(3),309-314","journal-title":"Prostate"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867326666191209142209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/177260\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867326666191209142209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T16:56:25Z","timestamp":1660582585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177260\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":31,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666191209142209","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}